Literature DB >> 21638077

Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.

Henriqueta Coimbra Silva1, Vera Alves, Luis Alcides Mesquita Nogueira, Manuel Santos Rosa, Lina Carvalho, Fernando Regateiro.   

Abstract

Inhibition of cyclooxygenase-2 (COX-2) is known to impair cancer cell metastatic behaviour, but the mechanisms involved largely remain elusive. We aimed to analyse whether the antimetastatic effect of COX-2 inhibition in breast cancer cells could be explained by variations in the expression levels of chemokine receptor CXCR4, vascular endothelium growth factor (VEGF) and UPA/UPAR components of the urokinase plasminogen activator system (uPAR). Breast cancer cell line MDA-MB-231 was exposed to COX-2-specific inhibitor NS398. Experimental data were assessed using Matrigel invasion tests, qRT-PCR, ELISA, flow cytometry and MTT test. Exposure to NS398 had no major effect on cell viability, apoptosis or VEGF production. Cell invasion was significantly decreased with reductions ranging from of 3.6% with 10 μM NS398 to 81.04% with 100 μM NS398. CXCR4 membrane expression was significantly reduced by 18% (P < 0.05) when cells were treated with 100 μM of NS398 for 72 h. UPA mRNA levels were significantly reduced to 78 and 63% after treatment with 10 μM NS398 for 48 and 72 h, respectively (P < 0.05). UPAR mRNA levels also decreased with mild NS398 concentrations, reaching the lowest level of 56% with 50 μM of NS398 for 48 h (P < 0.05). With NS398 higher concentrations, UPAR and UPA expression levels increased. According to our results, impairment of expression of CXCR4, UPA and UPAR differentially contribute to the antimetastatic effect of COX-2 inhibitors depending on drug concentration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21638077     DOI: 10.1007/s12032-011-9995-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.

Authors:  Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Zafrani; Marie-Christine Mathieu; Philippe Bertheau; Jean Marc Guinebretière; Marc Spielmann; Alexia Savignoni; Michel Marty
Journal:  Breast Cancer Res Treat       Date:  2010-05-18       Impact factor: 4.872

2.  Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells.

Authors:  Guoping Li; Tian Yang; Jun Yan
Journal:  Biochem Biophys Res Commun       Date:  2002-12-20       Impact factor: 3.575

Review 3.  Cyclooxygenases 1 and 2.

Authors:  J R Vane; Y S Bakhle; R M Botting
Journal:  Annu Rev Pharmacol Toxicol       Date:  1998       Impact factor: 13.820

4.  COX-2 overexpression increases motility and invasion of breast cancer cells.

Authors:  Balraj Singh; Jacob A Berry; Angela Shoher; Vijay Ramakrishnan; Anthony Lucci
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

5.  Silencing of CXCR4 blocks breast cancer metastasis.

Authors:  Zhongxing Liang; Younghyoun Yoon; John Votaw; Mark M Goodman; Larry Williams; Hyunsuk Shim
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

6.  Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.

Authors:  M J Duffy; C Duggan; H E Mulcahy; E W McDermott; N J O'Higgins
Journal:  Clin Chem       Date:  1998-06       Impact factor: 8.327

7.  Aromatase and COX in breast cancer: enzyme inhibitors and beyond.

Authors:  Robert W Brueggemeier; Bin Su; Yasuro Sugimoto; Edgar S Díaz-Cruz; Danyetta D Davis
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-25       Impact factor: 4.292

8.  Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression.

Authors:  Edmund Leung; David McArthur; Alan Morris; Nigel Williams
Journal:  Dis Colon Rectum       Date:  2008-01-29       Impact factor: 4.585

9.  Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

Authors:  Gargi D Basu; Latha B Pathangey; Teresa L Tinder; Sandra J Gendler; Pinku Mukherjee
Journal:  Breast Cancer Res       Date:  2005-04-04       Impact factor: 6.466

10.  Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells.

Authors:  G P Pidgeon; M P Barr; J H Harmey; D A Foley; D J Bouchier-Hayes
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

View more
  1 in total

1.  Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.

Authors:  Daniela Alfano; Anna Gorrasi; Anna Li Santi; Patrizia Ricci; Nunzia Montuori; Carmine Selleri; Pia Ragno
Journal:  J Cell Mol Med       Date:  2015-06-16       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.